Current status and future perspective of hepatic artery infusion chemotherapy

doi:10.16139/j.1007-9610.2020.01.003

Abstract

CLC Number:

R735.7

SHI Ming, HE Minke, CHEN Minshan. Current status and future perspective of hepatic artery infusion chemotherapy[J]. Journal of Surgery Concepts & Practice, 2020, 25(01): 10-14.

References 30

[1]	Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study[J]. JAMA Oncol, 2017, 3(4):524-548. doi: 10.1001/jamaoncol.2016.5688 pmid: 27918777
[2]	Benson AB, D'Angelica MI, Abbott DE, et al. Guidelines insights: hepatobiliary cancers, version 2.2019[J]. J Natl Compr Canc Netw, 2019, 17(4):302-310.
[3]	He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs. sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial[J]. JAMA Oncol, 2019, 5(7):953-960.
[4]	Song DS, Song MJ, Bae SH, et al. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis[J]. J Gastroenterol, 2015, 50(4):445-454.
[5]	Choi JH, Chung WJ, Bae SH, et al. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis[J]. Cancer Chemother Pharmacol, 2018, 82(3):469-478.
[6]	Lyu N, Kong Y, Mu L, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1):60-69.
[7]	Kudo M, Matsui O, Izumi N, et al. JSH Consensus-Based Clinical Practice Guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan[J]. Liver Cancer, 2014, 3(3-4):458-468.
[8]	Hiramine Y, Uto H, Imamura Y, et al. Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study[J]. Exp Ther Med, 2011, 2(3):433-441.
[9]	Jeong SW, Jang JY, Lee JE, et al. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma[J]. Asia Pac J Clin Oncol, 2012, 8(2):164-171.
[10]	Fukubayashi K, Tanaka M, Izumi K, et al. Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method[J]. Cancer Medicine, 2015, 4(8):1214-1223. doi: 10.1002/cam4.476 pmid: 26044168
[11]	Obi S, Sato S, Kawai T. Current status of hepatic arterial infusion chemotherapy[J]. Liver Cancer, 2015, 4(3):188-199.
[12]	He MK, Le Y, Li QJ, et al. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study[J]. Chin J Cancer, 2017, 36(1):83.
[13]	Chung YH, Song IH, Song BC, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis[J]. Cancer, 2000, 88(9):1986-1991. pmid: 10813709
[14]	Kawaoka T, Aikata H, Kobayashi T, et al. Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma[J]. Hepatol Res, 2018, 48(13):1118-1130.
[15]	Ikeda M, Okusaka T, Furuse J, et al. A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis[J]. Cancer Chemother Pharmacol, 2013, 72(2):463-470.
[16]	Nouso K, Miyahara K, Uchida D, et al. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan[J]. Br J Cancer, 2013, 109(7):1904-1907.
[17]	Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leuco-vorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol, 2013, 31(28):3501-3508.
[18]	Morito M, Masato S, Yuh S, et al. 5-fluorouracil arterial infusion + interferon therapy for highly advanced hepatocellular carcinoma: A multicenter, randomized, phase Ⅱ study[J]. Hepatol Res, 2012, 42(2):150-165. doi: 10.1111/j.1872-034X.2011.00905.x pmid: 22044786
[19]	Zhuang BW, Li W, Xie XH, et al. Sorafenib versus he-patic arterial infusion chemotherapy for advanced hepato-cellular carcinoma: a systematic review and meta-analysis[J]. Jpn J Clin Oncol, 2019, 49(9):845-855.
[20]	Ikeda M, Shimizu S, Sato T, et al. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: rando-mized phase Ⅱ trial[J]. Ann Oncol, 2016, 27(11):2090-2096. pmid: 27573564
[21]	Kudo M, Ueshima K, Yokosuka O, et al. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2018, 3(6):424-432.
[22]	He MK, Zou RH, Li QJ, et al. Phase Ⅱ Study of sorafenib combined with concurrent hepatic arterial infusion of oxaliplatin, 5-fluorouracil and leucovorin for unresectable hepatocellular carcinoma with major portal vein thrombosis[J]. Cardiovasc Intervent Radiol, 2018, 41(5):734-743.
[23]	Chong JU, Choi GH, Han DH, et al. Downstaging with localized concurrent chemoradiotherapy can identify optimal surgical candidates in hepatocellular carcinoma with portal vein tumor thrombus[J]. Ann Surg Oncol, 2018, 25(11):3308-3315. doi: 10.1245/s10434-018-6653-9 pmid: 30083834
[24]	Kodama K, Kawaoka T, Aikata H, et al. Comparison of outcome of hepatic arterial infusion chemotherapy combined with radiotherapy and sorafenib for advanced he-patocellular carcinoma patients with major portal vein tumor thrombosis[J]. Oncology, 2018, 94(4):215-222.
[25]	Hamaoka M, Kobayashi T, Kuroda S, et al. Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: A retrospective cohort study[J]. Int J Surg, 2017, 44:223-228.
[26]	Hatooka M, Kawaoka T, Aikata H, et al. Comparison of outcome of hepatic arterial infusion chemotherapy and sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization[J]. Anticancer Res, 2016, 36(7):3523-3529.
[27]	Ikeda M, Mitsunaga S, Shimizu S, et al. Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization[J]. J Gastroenterol, 2014, 49(5):932-940.
[28]	Moriya K, Namisaki T, Sato S, et al. Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma[J]. J Gastrointest Oncol, 2018, 9(4):741-749. doi: 10.21037/jgo.2018.05.13 pmid: 30151271
[29]	Shiozawa K, Watanabe M, Ikehara T, et al. Efficacy of sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization[J]. Gan To Kagaku Ryoho, 2015, 42(8):953-956.
[30]	Moran A, Ramos LF, Picado O, et al. Hepatocellular carcinoma: resection with adjuvant hepatic artery infusion therapy vs. resection alone. A systematic review and meta-analysis[J]. J Surg Oncol, 2019, 119(4):455-463.

Current status and future perspective of hepatic artery infusion chemotherapy

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 30

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	YE Feng, GONG Xiaoyong, REN Jiajun, CAI Qiang, CHEN Sheng. Application of ERCP in diagnosis and treatment of biliary complications during perioperative period of primary liver cancer [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 355-360.
[2]	CHANG Jessica, CHEN Xuxiao, CHEN Yongjun. Role of the spleen in patients with liver cancer and cirrhosis [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 394-398.
[3]	ZHANG Hui, GONG Ling, GUO Qian, LUO Yan. Retrospective study on sugammadex for reversal of neuromuscular blockade after radiofrequency ablation of hepatic carcinoma under general anesthesia [J]. Journal of Surgery Concepts & Practice, 2023, 28(01): 72-76.
[4]	ZHANG Jixiang, XIE Zhihua, LI Wei, JIANG Xiaoqing. Classification of intrahepatic cholangiocarcinoma and hot topics in surgical treatment [J]. Journal of Surgery Concepts & Practice, 2022, 27(05): 478-482.
[5]	YIN Yanjiang, LUO Zhiwen, CHEN Xiao, ZHANG Yefan, HUANG Zhen, ZHAO Hong, ZHAO Jianjun, LI Zhiyu, ZHOU Jianguo, CAI Jianqiang, BI Xinyu. Relationship between surgical margin and prognosis of patients with intrahepatic cholangiocarcinoma [J]. Journal of Surgery Concepts & Practice, 2022, 27(03): 221-228.
[6]	CHEN Congyan, WANG Junqing, CHEN Yongjun. Gut microbiota and mechanism of liver cancer [J]. Journal of Surgery Concepts & Practice, 2022, 27(03): 256-260.
[7]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 93-94.
[8]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 95-99.
[9]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 100-106.
[10]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 107-112.
[11]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 113-118.
[12]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 119-122.
[13]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 123-127.
[14]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 128-130.
[15]	. [J]. Journal of Surgery Concepts & Practice, 2022, 27(02): 131-133.